Clinical and instrumental comparison between insufficient sleep syndrome and narcolepsy type 1
Abstract
Insufficient sleep syndrome (ISS) and narcolepsy type 1 (NT1) both feature excessive daytime sleepiness (EDS), yet they differ in etiology and nighttime sleep architecture. We compared clinical characteristics, video-polysomnography (v-PSG), Multiple Sleep Latency Test (MSLT), and actigraphy in ISS and NT1, to better define ISS and differentiate the two disorders. We retrospectively screened patients from a Sleep Medicine Unit who had a confirmed diagnosis of ISS (n = 23) or NT1 (n = 9) and underwent v-PSG, MSLT, and actigraphy. All patients were drug-free, and those with comorbid sleep disorders were excluded. Clinical data were collected through structured interviews, sleep diaries, and standardized questionnaires. Subjective EDS, reported by both ISS and NT1 groups, was similar in severity. MSLT showed that nearly one-third of ISS patients exhibited sleep-onset REM periods (SOREMPs), highlighting the risk of overlap with NT1. In v-PSG, ISS was characterized by high sleep efficiency and a low arousal index; no major differences in sleep parameters emerged between ISS and NT1. Actigraphy provided relevant data: ISS displayed weekday sleep restriction with weekend compensation, whereas NT1 showed fragmented but prolonged nighttime sleep and more frequent daytime naps. Overall, the variability in sleep patterns (time in bed and total sleep time) was more pronounced in ISS on weekends, whereas NT1's hallmark was nighttime fragmentation. While ISS and NT1 overlap in EDS, they…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 23 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.